文献速递心律失常

RYR2介导的儿茶酚胺敏感性多形性室速风险分层模型

Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification.
PubMed 文献 · Eur Heart J · 2026-01-01

研究基于743例推导队列和129例验证队列,开发并外部验证了RYR2介导的CPVT患者接受β受体阻滞剂单药治疗期间心律失常事件的Cox回归预测模型;模型纳入诊断前心律失常性晕厥或心脏骤停及β受体阻滞剂起始年龄等预测因子,对AE和近致命/致命AE具有一定区分度。

要点

  • 模型可区分β受体阻滞剂单药治疗CPVT患者的低危及高危心律失常事件风险。
  • AE预测因子包括诊断前心律失常性晕厥或SCA及β受体阻滞剂起始年龄。
  • 近致命/致命AE预测还纳入β受体阻滞剂起始前室性心律失常严重程度。

核心结论

  • 外部验证的风险预测模型可较准确区分β受体阻滞剂单药治疗的CPVT患者未来发生AE的低风险与高风险。
  • 模型可为CPVT患者预防AE的临床管理措施提供指导。

研究设计与样本

  • 推导队列743例和独立验证队列129例RYR2介导的CPVT患者,均接受β受体阻滞剂单药治疗。
  • 采用Cox回归开发预测模型,并进行内部验证和外部验证。
  • AE定义为心律失常性晕厥、适当的植入式心律转复除颤器放电、心脏骤停和心源性猝死;nf/fAE为除心律失常性晕厥外的所有AE。

主要发现

  • 推导队列102例(13.7%)和验证队列24例(18.6%)患者在中位随访5.1年(IQR 7.7)和2.4年(IQR 4.4)内发生至少1次AE。
  • AE预测因子为诊断前心律失常性晕厥或SCA及β受体阻滞剂起始年龄。
  • AE模型乐观校正C指数在推导队列为0.67(95%CI 0.62-0.72),验证队列为0.59(95%CI 0.48-0.71)。
  • nf/fAE模型加入β受体阻滞剂起始前室性心律失常严重程度作为第四个独立预测因子,推导队列C指数0.74(95%CI 0.68-0.80),验证队列0.60(95%CI 0.47-0.72)。
  • 推导队列校准斜率AE为1.00(95%CI 0.59-1.41),nf/fAE为1.00(95%CI 0.69-1.32)。

关键数值与推荐

  • AE预测模型纳入诊断前心律失常性晕厥或SCA及β受体阻滞剂起始年龄。
  • nf/fAE预测模型额外纳入β受体阻滞剂起始前室性心律失常严重程度。

临床怎么用

  • 对RYR2介导的CPVT患者启动β受体阻滞剂治疗时,可基于诊断前晕厥/SCA史、起始年龄及室性心律失常严重程度评估未来AE风险。
  • 风险分层有助于识别高危患者并指导临床管理措施以预防AE。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with β-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on β-blocker monotherapy. METHODS: The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter-defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. RESULTS: A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced ≥1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at β-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62-0.72] and 0.59 (95% CI 0.48-0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before β-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68-0.80) and 0.60 (95% CI 0.47-0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59-1.41) for AE and 1.00 (95% CI 0.69-1.32) for nf/fAE. CONCLUSIONS: These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on β-blocker monotherapy at low and high risk for future AEs while treated with β-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lieve KV, van der Werf C, Kallas D, et al. Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification. Eur Heart J. 2026. PMID: 41416846. doi:10.1093/eurheartj/ehaf965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。